[go: up one dir, main page]

PE20210108A1 - Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma - Google Patents

Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma

Info

Publication number
PE20210108A1
PE20210108A1 PE2020000943A PE2020000943A PE20210108A1 PE 20210108 A1 PE20210108 A1 PE 20210108A1 PE 2020000943 A PE2020000943 A PE 2020000943A PE 2020000943 A PE2020000943 A PE 2020000943A PE 20210108 A1 PE20210108 A1 PE 20210108A1
Authority
PE
Peru
Prior art keywords
ige
composition
polypeptide
probiotics
present
Prior art date
Application number
PE2020000943A
Other languages
English (en)
Inventor
Myoung Ho Jang
Young Chul Sung
Zungyoon Yang
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of PE20210108A1 publication Critical patent/PE20210108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a una composicion que contiene, como ingredientes activos, probioticos y un polipeptido con capacidad de union a IgE. En particular, se identifico un efecto sinergico de disminucion notable de la alergia alimentaria en el momento de la administracion combinada de probioticos y una proteina recombinante que contiene un dominio extracelular de una subunidad alfa de un receptor Fc de IgE de conformidad con la presente invencion. Por lo tanto, se espera que la composicion de la presente invencion sea altamente aplicable industrialmente debido a que puede presentar un efecto terapeutico notable sobre una enfermedad alergica mediada por IgE en comparacion con las composiciones farmaceuticas convencionales
PE2020000943A 2018-01-12 2019-01-14 Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma PE20210108A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180004421 2018-01-12
PCT/KR2019/000524 WO2019139434A1 (ko) 2018-01-12 2019-01-14 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도

Publications (1)

Publication Number Publication Date
PE20210108A1 true PE20210108A1 (es) 2021-01-19

Family

ID=67218660

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000943A PE20210108A1 (es) 2018-01-12 2019-01-14 Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma

Country Status (18)

Country Link
US (1) US12128076B2 (es)
EP (1) EP3738599B1 (es)
JP (1) JP7041272B2 (es)
KR (1) KR102038679B1 (es)
CN (1) CN111587118B (es)
AU (1) AU2019206205B2 (es)
BR (1) BR112020013818A2 (es)
CA (1) CA3086224A1 (es)
CL (1) CL2020001800A1 (es)
ES (1) ES2969110T3 (es)
IL (1) IL275593B (es)
MX (1) MX2020007032A (es)
MY (1) MY205046A (es)
PE (1) PE20210108A1 (es)
PH (1) PH12020551069A1 (es)
SG (1) SG11202005863TA (es)
TW (1) TWI737955B (es)
WO (1) WO2019139434A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7128291B2 (ja) * 2018-01-08 2022-08-30 ジーアイ・イノベイション・インコーポレイテッド ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
WO2020172473A1 (en) * 2019-02-20 2020-08-27 Siolta Therapeutics, Inc. Compositions for disease treatment
JP7579815B2 (ja) * 2019-07-08 2024-11-08 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物
JP7784412B2 (ja) * 2020-07-17 2025-12-11 ジーアイ イノベーション， インコーポレイテッド Ｉｇｅ ｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用
KR20220011931A (ko) * 2020-07-22 2022-02-03 (주)지아이이노베이션 IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JPH10309178A (ja) * 1997-05-09 1998-11-24 Wakamoto Pharmaceut Co Ltd ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品
JP2000095697A (ja) * 1998-09-18 2000-04-04 Advance Co Ltd 抗アレルギー剤
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
JP2009067679A (ja) 2005-12-27 2009-04-02 Univ Of Tokushima 抗ヒスタミン作用を有する医薬
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
DK2662449T3 (en) 2007-05-30 2017-05-15 Postech Academy-Industry- Found immunoglobulin fusion proteins
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
US20090196921A1 (en) * 2008-02-06 2009-08-06 The Procter & Gamble Company Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
PT2853545T (pt) 2008-09-17 2016-08-26 Xencor Inc Anticorpo específico para ige
MY182750A (en) * 2009-10-26 2021-02-05 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
KR20120135865A (ko) * 2011-06-07 2012-12-17 (주)네오팜 ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
CN103169733B (zh) 2011-12-26 2014-11-12 浙江贝因美科工贸股份有限公司 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
CN107949393A (zh) * 2015-03-12 2018-04-20 不列颠哥伦比亚大学 细菌组合物及其应用方法
KR101778734B1 (ko) 2016-03-11 2017-09-18 대한민국(농촌진흥청장) 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물
JP7128291B2 (ja) * 2018-01-08 2022-08-30 ジーアイ・イノベイション・インコーポレイテッド ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
WO2019135666A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
AU2019206205B2 (en) 2025-04-10
EP3738599C0 (en) 2023-12-27
CN111587118A (zh) 2020-08-25
CL2020001800A1 (es) 2020-10-30
KR20190086396A (ko) 2019-07-22
TW201932129A (zh) 2019-08-16
IL275593A (en) 2020-08-31
US12128076B2 (en) 2024-10-29
PH12020551069A1 (en) 2021-09-06
TWI737955B (zh) 2021-09-01
BR112020013818A2 (pt) 2020-12-01
RU2020122021A (ru) 2022-02-14
IL275593B (en) 2022-01-01
AU2019206205A1 (en) 2020-06-25
JP7041272B2 (ja) 2022-03-23
ES2969110T3 (es) 2024-05-16
SG11202005863TA (en) 2020-07-29
EP3738599B1 (en) 2023-12-27
MX2020007032A (es) 2020-12-03
KR102038679B1 (ko) 2019-10-30
CN111587118B (zh) 2023-11-21
JP2021510689A (ja) 2021-04-30
US20220347236A1 (en) 2022-11-03
MY205046A (en) 2024-09-29
CA3086224A1 (en) 2019-07-18
EP3738599A4 (en) 2021-10-27
EP3738599A1 (en) 2020-11-18
WO2019139434A1 (ko) 2019-07-18

Similar Documents

Publication Publication Date Title
CL2020001800A1 (es) Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma.
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
MX2024004936A (es) Variantes de capsides de aav y sus usos.
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
CO2019011021A2 (es) Formulacion estable de anticuerpos
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
EA202090890A1 (ru) Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
BR112016014969A2 (pt) polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
AR093387A1 (es) Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina
CL2016001405A1 (es) A peptide mixture
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
PH12020551500A1 (en) Viscosity reduction of highly concentrated protein formulations
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
PE20151866A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
DOP2019000156A (es) Fenitoina topica para uso en el tratamiento del dolor neuropático periférico
MX2020010030A (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
CU20210008A7 (es) Aspirasas solubilizadas
AR117306A1 (es) Polipéptidos que tienen actividad de fitasa